2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Transfusion, Transplantation, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Bleeding and Clotting, Bleeding Disorders, Hemophilia, Thromboembolism, Thrombocytopenias, Thrombotic Disorders, Bone Marrow Failure Syndromes, Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Genetic Disorders, Immunology, Autoimmune Hemolytic Anemia, GVHD, Infectious Diseases, Bacterial, Metabolic Disorders, Iron Deficiency, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Pediatric
PAPER

4472 Comparative safety and overall survival of apixaban versus rivaroxaban in splanchnic vein thrombosis: A propensity-matched real-world analysis

Vaishali Deenandayalan, MD, Vasanthan Kumarasamy, MD2, Devinderpal S Randhawa, MD3
1 Roswell Park Comprehensive Cancer Center, Buffalo, United States
2 Roswell Park Comprehensive Cancer Center, Buffalo, United States
3 University at Buffalo, Buffalo, United States

Background:

Splanchnic vein thrombosis (SVT), encompassing portal, mesenteric, and hepatic vein thromboses, presents a complex clinical challenge due to overlapping risks of life-threatening bleeding and recurrent thrombosis. While Direct Oral Anticoagulants (DOACs) are increasingly utilized off-label for SVT, head-to-head comparative data to guide the choice between specific agents are lacking. This study aimed to compare the 1-year risks of gastrointestinal (GI) hemorrhage (ICD-10 K92.0–K92.2, I85.0, K25–K28, K29.81, K31.811, K31.82, K55.21, K57) and all-cause mortality between patients prescribed apixaban versus rivaroxaban for SVT.

Methods:

A retrospective cohort study was conducted using the TriNetX global federated health research network. Adult patients (≥18 years) with a new diagnosis of SVT (ICD-10: I81, I82.0, K55.02) who were initiated on either apixaban or rivaroxaban were identified. To isolate the SVT cohort, patients with concurrent pulmonary embolism, deep vein thrombosis of the extremities and end-stage renal disease were strictly excluded. Those on warfarin, enoxaparin, heparin or dabigatran were excluded as well.  Propensity score matching (1:1) was utilized to balance the cohorts for baseline demographics, comorbidities and crucial bleeding or clotting risk factors, including liver cirrhosis, esophageal varices, and malignancies. Kaplan-Meier survival analysis and Cox proportional hazards models were used to evaluate 1-year outcomes.

Results:

Following propensity score matching, 1,558 patients were included in the final analysis, with 779 patients in the apixaban cohort and 779 patients in the rivaroxaban cohort. The mean ages of the apixaban and rivaroxaban groups were 65.4 and 63.3 years, respectively. The study population was predominantly White (68.91% apixaban vs. 63.5% rivaroxaban), followed by African American (7.97% vs. 8.65%) and Hispanic (6.65% vs. 7.2%) patients.

At 1-year follow-up, there was no statistically significant difference in all-cause mortality between the apixaban and rivaroxaban groups (log-rank p=0.2024). Mortality occurred in 67 patients receiving apixaban and 60 patients receiving rivaroxaban. The 1-year survival probability was 88.7% for apixaban and 90.7% for rivaroxaban (Hazard Ratio [HR]: 1.25; 95% CI: 0.89-1.78; p=0.5821).

Similarly, the primary safety outcome of major GI hemorrhage showed no significant difference between the cohorts (log-rank p=0.3993). GI bleeding events occurred in 46 patients on apixaban and 42 patients on rivaroxaban. The probability of remaining free from GI hemorrhage at 1 year was 92.5% in the apixaban cohort compared to 93.7% in the rivaroxaban cohort (HR: 1.20; 95% CI: 0.79-1.82; p=0.8661).

Conclusion:

In this large, propensity-matched real-world cohort, the use of apixaban or rivaroxaban for SVT demonstrated comparable 1-year safety and overall survival profiles. Neither agent showed statistical superiority regarding the prevention of all-cause mortality or gastrointestinal hemorrhage. These findings suggest that both DOACs represent reasonable therapeutic options for SVT management in clinical practice. Limitations inherent to retrospective EHR analyses apply, and further randomized prospective trials are warranted to confirm these real-world findings.

Vaishali Deenandayalan, MD: No relevant conflicts of interest to declare.